PL328096A1 - Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines - Google Patents

Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines

Info

Publication number
PL328096A1
PL328096A1 PL97328096A PL32809697A PL328096A1 PL 328096 A1 PL328096 A1 PL 328096A1 PL 97328096 A PL97328096 A PL 97328096A PL 32809697 A PL32809697 A PL 32809697A PL 328096 A1 PL328096 A1 PL 328096A1
Authority
PL
Poland
Prior art keywords
yeasts
vaccines
protein
expression
group
Prior art date
Application number
PL97328096A
Other languages
English (en)
Inventor
Joseph Y Tai
Mikhail Donets
Ming-Der Wang
Shu-Mei Liang
Maryellen Polvino-Bodnar
Conceicao A S A Minetti
Francis Michon
Original Assignee
North American Vaccine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine filed Critical North American Vaccine
Publication of PL328096A1 publication Critical patent/PL328096A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL97328096A 1996-02-01 1997-01-31 Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines PL328096A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1097296P 1996-02-01 1996-02-01
US2044096P 1996-06-13 1996-06-13

Publications (1)

Publication Number Publication Date
PL328096A1 true PL328096A1 (en) 1999-01-04

Family

ID=26681820

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97328096A PL328096A1 (en) 1996-02-01 1997-01-31 Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines

Country Status (9)

Country Link
EP (1) EP0877816A1 (xx)
JP (1) JP2001508758A (xx)
KR (1) KR19990082265A (xx)
AU (1) AU2115897A (xx)
HU (1) HUP9901039A2 (xx)
IL (1) IL125420A0 (xx)
NO (1) NO983474L (xx)
PL (1) PL328096A1 (xx)
WO (1) WO1997028273A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502437A (en) 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP4524816B2 (ja) * 1998-07-06 2010-08-18 東ソー株式会社 Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
EA006233B1 (ru) 1999-05-13 2005-10-27 Уайт Холдингз Корпорейшн Комбинированные адъювантные композиции для усиления иммунного ответа у позвоночного животного
EP1179072A2 (en) * 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
EP1069133A1 (en) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
JP4840956B2 (ja) * 1999-11-29 2011-12-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ８５ｋＤａのナイセリア抗原
DK1248647T3 (da) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
PT1947187E (pt) 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Expressões híbridas de proteínas de neisseria
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
SI2351579T1 (sl) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
JP2006262846A (ja) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk 酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース
KR100919704B1 (ko) * 2007-09-12 2009-10-06 한국생명공학연구원 효모에서 재조합단백질을 고효율로 분비발현시키는 방법
JP2011116658A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
CN106146679B (zh) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 一种纯化细菌荚膜多糖的方法
CN109153979A (zh) * 2015-12-30 2019-01-04 帝斯曼知识产权资产管理有限公司 三酰基甘油的部分酶水解
JP2022529021A (ja) * 2019-04-17 2022-06-16 インポッシブル フーズ インコーポレイテッド タンパク質作製の材料および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

Also Published As

Publication number Publication date
AU2115897A (en) 1997-08-22
EP0877816A1 (en) 1998-11-18
IL125420A0 (en) 1999-03-12
HUP9901039A2 (hu) 1999-07-28
KR19990082265A (ko) 1999-11-25
WO1997028273A1 (en) 1997-08-07
JP2001508758A (ja) 2001-07-03
NO983474L (no) 1998-09-30
NO983474D0 (no) 1998-07-28

Similar Documents

Publication Publication Date Title
PL328096A1 (en) Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
PL312712A1 (en) High level expression, purification and repeated creasing of group b(porynowe?) proteins of outer membrane of neisseria meningitidis
DK0486290T3 (da) Fremgangsmåde og præparat til forøgelse af akkumulering af squalen og specifikke steroler i gær
GB2314013B (en) Integrated dental chair and post-mounted delivery system
EP0895535A4 (en) REPLICATION OF INFLUENZA VIRUS IN MAMMALIAN CELL CULTURE AND VACCINE PRODUCTION
HUP9800901A3 (en) Process, medium and cell culture system for the preparation of recombinant factor viii in a protein free medium
PL322589A1 (en) Radiotracer-labelled peptides for use in diagnostics and therapy
NO992779D0 (no) OB-fusjonsproteinpreparater og fremgangsmÕte for fremstilling av slike
HUP9904237A3 (en) Expression of globin proteins in plants
PL329350A1 (en) Autoantigen and structural proteins affinite thereto for application in immunotherapy used in treatment of autoimmunisation diseases
IL93957A0 (en) Bordetella outer membrane proteins,their use in vaccines and their expression
IL111047A0 (en) Preparations based on fermented whey and their uses
AU5175798A (en) Membrane and methods of preparing and using same
GB2275029B (en) Improvements in and relating to wheelchairs
AU3636195A (en) Support post for use in dental implant system
CZ202497DA3 (en) Glycoproteins rich in hydroxy proline and preparations containing thereof
EP0766741A4 (en) GM-CSF CONTAINED FUSION PROTEINS AND ANTIGENS AND THEIR EXPRESSION IN YEAST
EE9800188A (et) N-atsetüül-(L)-4-tsüanofenüülalaniini Ac-(L)-Phe- (4-CN)-OH ja N-atsetüül- (L)-p-amidinofenüülalaniintsükloheksüülglütsiin-ß- (3-N-metüülpüridiinium)alaniini Ac-(L)-pAph-Chg-PalMe(3)-NH2 valmistamismeetod
GB9523497D0 (en) Cell membrane protein and application thereof
AU3956195A (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
AU5735299A (en) Basb024 outer membrane protein of neisseria meningitidis
IL98839A0 (en) Vaccines comprising protein of the outer membrane of neisseria meningitidis
DE69504214T2 (de) Regelungsverfahren und -system zur Rücksaugvermeidung bei mit Turbinen angetriebenen dentalen Behandlungsinstrumenten
AU5978596A (en) Liposomes containing human immunodeficiency virus glycoprote in and methods for use thereof